TBIP signs a cooperation agreement with international companies Merck and Thermo Fisher Scientific
Creating a Quality Innovation Cooperation Environment and Co-Creating a Biomedical Industry Ecosystem
Taipei, July 26, 2024 — In 2018, Sekon Development Co., Ltd., in partnership with the Taipei City Government, established the Taipei BioInnovation Park (TBIP). Since its completion and operation in March 2023, the park has achieved an overall occupancy rate of over 90%. Today, at the Bio Asia-Taiwan 2024 exhibition, Taipei Mayor Chiang Wan-an witnessed the signing of a Memorandum of Understanding (MOU) between Sekon Development Chairman Huang Mao-hsiung, representing the Taipei Biomedical Park, and the international giants Merck and Thermo Fisher Scientific. Through collaboration with these international companies, the Taipei Biomedical Park aims to further provide a high-quality innovative cooperation environment, integrating resources from various industries, government, and research institutions to co-create a biomedical industry ecosystem.
The cooperation agreement between TBIP and the international companies Merck and Thermo Fisher Scientific was witnessed by Taipei Mayor Chiang Wan-an (center). In his speech, the Mayor stated that witnessing the signing of R&D resource cooperation agreements between Sekon Development and international giants like Merck and Thermo Fisher strengthens Taipei’s research and development capabilities in the biomedical field. He expressed his hope that Taipei’s biotech industry would rapidly advance and become a shining star in the global biotech sector.
Introducing Cutting-Edge Research and Pilot Production Capabilities in Biotech R&D
The two international leading companies signing the cooperation agreement with Taipei Biomedical Park play significant roles in the development of the biomedical industry, from cutting-edge research to pilot production development.
Merck
The MOU between TBIP and Merck Taiwan was signed with Taipei Mayor Chiang Wan-an (center) witnessing the event. From left: Sekon Development Co., Ltd. Special Consultant Chien Tsung-liang, Chairman Huang Mao-hsiung, Merck Taiwan General Manager Lee Chun-lung, and Claire Lee, Senior Director of Process Solutions, Life Science Business, Merck East Asia and Oceania.
TBIP and the globally leading science and technology company Merck are collaborating to establish the sixth M Lab™ Collaboration Center in Asia at the park. This is Taiwan’s first technology service laboratory established by an international bioprocess supplier, covering the entire biopharmaceutical process and supporting customer needs from preclinical testing to commercial production. Additionally, employing Biopharma 4.0 technology, it supports new therapies, next-generation bioprocessing, and digital bioprocessing demonstrations. Combining Merck's extensive practical experience and international technical network with Taiwan’s advantages in biopharmaceutical and ICT technologies, the center offers diverse intelligent solutions for biotech and pharmaceutical R&D companies. Over 300 global professional instructors will conduct talent training, supporting cross-domain collaboration development and enhancing Taiwan's biopharmaceutical industry's resilience through optimized value chains and improved R&D and production capabilities.Thermo Fisher Scientific
The MOU between TBIP and Thermo Fisher Scientific was signed with Taipei Mayor Chiang Wan-an (center) witnessing the event. From left: Sekon Development Co., Ltd. Special Consultant Chien Tsung-liang, Chairman Huang Mao-hsiung, Thermo Fisher Scientific Taiwan General Manager Hung Chong-yu, and Biosciences Business Manager Weng Chen-che.
TBIP and the global biotech service giant Thermo Fisher Scientific are partnering to establish Taiwan's first biotech incubation dedicated intelligent shared laboratory. This facility provides startups with advanced instruments and equipment, exclusive lab operation spaces, comprehensive technical support services, a convenient online reservation system, and an intelligent supply center. This environment is designed to foster R&D capabilities, improve experimental processes, optimize production processes, and develop innovative products. Additionally, Thermo Fisher Scientific will establish its Taiwan operations headquarters at the park, integrating multiple leading brands in fields including healthcare, life sciences, pharmaceuticals, biotechnology, and applied sciences. This headquarters will support the R&D and clinical needs of the Taipei Biomedical Park and surrounding areas. Furthermore, an advanced technology demonstration laboratory will be set up to host scientific knowledge and innovative technology workshops, enhancing R&D team technical capabilities and providing optimal solutions to accelerate product commercialization, thereby realizing the value of R&D to actual industry application.Looking at the global biomedical market, creating TBIP as an international biotech innovation hotspot
Century Biotech Development Chairman Huang Mao-hsiung stated that the opening of the Taipei Biomedical Park has attracted many key domestic and international biomedical and pharmaceutical industries and multinational companies. The choice of Merck's M Lab™ and Thermo Fisher Scientific to establish bioprocessing laboratories and operations headquarters at the park signifies Taipei Biomedical Park's importance in Taiwan's biotech industry. Through collaboration with international giants, the park will introduce professional training courses, technical services, and R&D resources, enhancing the professional quality and R&D capabilities of domestic biomedical talents, promoting technological innovation, and accelerating the development of potential new drugs and advanced medical devices and smart health services, aiming to recreate Taiwan's protective industry.
In the future, TBIP will strive to perfect the biomedical industry ecosystem, attract international investment, promote cross-domain market cooperation, and accelerate startup funding matching, facilitating full exchange of capital, talent, and technology, sparking industry innovation and driving Taiwan's biomedical industry to new heights..
For further information, please contact：
Century Biotech Development
Yang Chia-lin, Associate General Manager (Phone: +886-2-2651-6868 ext. 500 / Mobile: +886-988-856-020)
You Chiu-hung, Senior Specialist (Phone: +886-2-2651-6868 ext. 505 / Mobile: +886-958-916-466)
Email: info@tbip.com.tw
This press release showcases the cooperation between Taipei Biomedical Park and Merck and Thermo Fisher Scientific. Through this international cooperation opportunity, they will jointly expand Taiwan's biomedical industry to the global market, highlighting Taipei Biomedical Park's important position in the global biomedical cluster and its future development potential.
